Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
5.23
+0.01 (0.19%)
At close: Nov 20, 2024, 4:00 PM
5.31
+0.08 (1.53%)
Pre-market: Nov 21, 2024, 4:04 AM EST
Amylyx Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 196.49 | 380.79 | 22.23 | 0.29 | 0.65 | 1.43 |
| Revenue Growth (YoY) | -33.22% | 1612.94% | 7700.00% | -56.15% | -54.42% | - |
| Cost of Revenue | 296.3 | 153.63 | 96.44 | 44.04 | 24.59 | 11.9 |
| Gross Profit | -99.82 | 227.16 | -74.21 | -43.76 | -23.94 | -10.47 |
| Selling, General & Admin | 149.48 | 188.36 | 127.13 | 38.93 | 15.06 | 3.08 |
| Operating Expenses | 149.48 | 188.36 | 127.13 | 38.93 | 15.06 | 3.08 |
| Operating Income | -249.29 | 38.8 | -201.34 | -82.69 | -39.01 | -13.55 |
| Interest Expense | - | - | - | - | -2.29 | -1.28 |
| Interest & Investment Income | 15.86 | 16.16 | 4.29 | 0.04 | 0.01 | 0.18 |
| Other Non Operating Income (Expenses) | -11.14 | -10.6 | -2.61 | 0.07 | -1.27 | 0.94 |
| EBT Excluding Unusual Items | -244.57 | 44.36 | -199.66 | -82.58 | -42.55 | -13.72 |
| Gain (Loss) on Sale of Investments | 9.94 | 9.94 | 2.06 | -0.12 | - | - |
| Other Unusual Items | - | - | - | -5.23 | 0.27 | - |
| Pretax Income | -257.48 | 54.3 | -197.6 | -87.93 | -42.28 | -13.72 |
| Income Tax Expense | 1.99 | 5.03 | 0.77 | - | - | - |
| Net Income | -259.47 | 49.27 | -198.38 | -87.93 | -42.28 | -13.72 |
| Net Income to Common | -259.47 | 49.27 | -198.38 | -87.93 | -42.28 | -13.72 |
| Shares Outstanding (Basic) | 68 | 67 | 58 | 7 | 6 | 6 |
| Shares Outstanding (Diluted) | 68 | 70 | 58 | 7 | 6 | 6 |
| Shares Change (YoY) | -1.59% | 19.65% | 788.13% | 8.37% | 3.20% | - |
| EPS (Basic) | -3.82 | 0.73 | -3.39 | -13.35 | -6.96 | -2.33 |
| EPS (Diluted) | -3.83 | 0.70 | -3.39 | -13.35 | -6.96 | -2.33 |
| Free Cash Flow | -131.78 | 10.68 | -182.4 | -75.15 | -36.85 | -10.69 |
| Free Cash Flow Per Share | -1.94 | 0.15 | -3.12 | -11.41 | -6.06 | -1.81 |
| Gross Margin | -50.80% | 59.66% | - | - | - | - |
| Operating Margin | -126.88% | 10.19% | -905.72% | -29013.33% | -6000.77% | -950.49% |
| Profit Margin | -132.05% | 12.94% | -892.38% | -30852.98% | -6504.62% | -961.85% |
| Free Cash Flow Margin | -67.07% | 2.80% | -820.50% | -26369.12% | -5668.92% | -749.44% |
| EBITDA | -248.25 | 39.89 | -200.85 | -82.64 | -39 | - |
| EBITDA Margin | -126.34% | 10.48% | - | - | - | - |
| D&A For EBITDA | 1.05 | 1.09 | 0.49 | 0.05 | 0 | - |
| EBIT | -249.29 | 38.8 | -201.34 | -82.69 | -39.01 | -13.55 |
| EBIT Margin | -126.88% | 10.19% | - | - | - | - |
| Effective Tax Rate | - | 9.26% | - | - | - | - |
| Revenue as Reported | 380.79 | 380.79 | 22.23 | 0.29 | - | - |
| Advertising Expenses | - | 9.5 | 4.4 | - | - | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.